Translating nonclinical safety and PK/PD data into informed clinical decision-making for CNS drug development.
Developing novel neurotherapeutics presents unique scientific and regulatory challenges. CNS exposure, seizure risk, blood–brain barrier penetration, and interspecies sensitivity all introduce uncertainty as programs transition from nonclinical research into the clinic.
This webinar, examines practical approaches to assessing and managing CNS risk using nonclinical pharmacology, toxicology, and PK/PD data. Through regulatory-informed frameworks and real-world case examples, the discussion highlights how early signals can be translated into safer, more informed clinical strategies.
What you’ll learn:
- How CNS risk is identified, characterized, and assessed from nonclinical data
- Key regulatory considerations shaping early neurotherapeutic development
- The role of exposure–response and safety margins in dose selection
- How modeling and simulation can support clinical decision-making
- Practical examples of de-risking first-in-human study design
© 2026 Marketing Masters Hub . All rights reserved.